
## Harnessing routinely-collected data for

## efficient and low-cost clinical trials

#### **Guilherme Pessoa-Amorim**

NIHR Clinical Research Fellow

Clinical Trial Service Unit & Cardiovascular Medicine Division, University of Oxford






iffield Department of OPULATION HEALTH edical Sciences Division





#### WHY DO WE CARE ABOUT TRIALS?








MRC Research Unit



#### WHY DO WE CARE ABOUT TRIALS?



RCTs are the best way to reliably establish and quantify a causal relation between an exposure and an outcome





### WHY DO WE CARE ABOUT TRIALS?

#### **Observational data can provide unreliable estimates:**

<b>Different effect size</b> (beta-blocker use and mortality after myocardial infarction)	202	β-blocker*	No β-blocker*	12
	Observational study‡ Randomised trials	~123/785 (16%) 827/10 452 (8%)	그는 것이 같은 것이 같은 것이 많은 것이 같이 다니 중 것이?	0-57 (0-47-0-69) 0-77 (0-70-0-85)
	ų.	CHD events/patient	ts	Risk ratio† (95% CI)
Different direction of apparent effect		Antihypertensive therapy*	No antihypertensive therapy*	

Randomised trials

#### Discordance regarding **presence** of effect

(higher-dose vs lower-dose aspirin and stroke after carotid endarterectomy)

	Stroke/patients	Risk ratio† (95%Cl)	
	Lower-dose aspirin (<650 mg daily)*	Higher-dose aspirin (650–1300 mg daily)*	
Observational study	96/1391 (7%)	15/835 (2%)	2-3 (1-3-3-9)
Randomised trial	64/1417 (5%)	86/1432 (6%)	0-74 (0.53-1.03)

1104/23 806 (5%)

Deaths/patients

934/23847(4%)





Stephen MacMahon and Rory Collins, Lancet 2001; 357: 455-62



Risk ratio† (95% CI)

0.84 (0.77-0.92


### **DON'T DITCH RANDOMIZATION!**

VS

#### **NON-RANDOMIZED METHODS**

#### **STREAMLINING RCTS**









### **STREAMLINED RANDOMIZED TRIALS**

- Focusing on the things needed to
  - Answer the research question
  - Keep the participants safe
- CTTi 'Quality by Design' principles
- Data enabled clinical trials
  - Health Data Research UK
  - Collaboration with NHS Digital NHS DigiTrial













#### **CLINICAL TRIALS VS ROUTINE HEALTH CARE**

**Trial data** collection systems

**Study visits** 

Participant questionnaires

Trial laboratory tests



Routine health care data collection systems

Hospital Admission Data Primary Care Systems Prescribing Mental Health Registries Screening programs





#### **Trial records**

• Answer the research question **reliably** 

### • Keep participants safe

• Keep participants' data safe



#### Routine health care records

- Record patient care reliably
- Keep patients safe
- Keep patients' data safe







Participant ID	460001451	NHS (or CHI number in Scotland)		Parti
National Identifier		Participant initials	AB	Date
Participant Name	Anna Bullivant	Date of Birth	01-jan-1950	
Sex	Female			
LCC	New site DEMO UK (41598)			

Participant ID	460001451
Date of birth	01-Jan-1950
Sex	Female
Race	Mixed
Title	Ms
First name	Anna
Family name	Bullivant
Initials	AB
Address	98 The Lane
Postcode/Zipcode	JH8 8YY
GP practice	PARADISE MEDICAL CENTRE BROAD STREET COVENTRY CV6 5BG Tel. 02476689343





letion Healt

Participant ID	460001451	NHS (or	CHI number in Scotland)			Participant ID	460001451	
National Identifier		Particip	ant Initials	AB	11	Date of birth	01-Jan-1950	
Participant Name	Anna Bullivant	Date of	Birth	01-jan-1950		Sex	Female	
Sex	Female					_		
LCC	New site DEMO U	K (41598)				Race	Mixed	
Ir	Screening vis nclusion criteria and	it: Medical history d relevant medical history		Screening visit Exclusion (	Medical history riteria Part 1			zation visit: le Events
			Has had an acute coronary	y syndrome in the last 4 weeks	No	Myocardial infarction		No
Myocardial infarction		No	is due to undergo a corona (angioplasty, stent or bypa	ary revascularisation procedure ss graft) within the next 6	No	Stroke or transient ischaemic a	attack	No
Coronary artery bypass graft		No	months	and and and and and and a		Percutaneous coronary interve stant or angioplasty	ention (PCI), e.g. coronary	No
Coronary artery angioplasty or stent (PC	1)	No	Is known to have chronic i		No	Coronary artery bypass surger	v	No
Stroke		No	Has previously had, or is p transplant	lanned to have, a kidney	No	Non-coronary arterial surgery		No
		22(1)	is on, or is planned to start	t, dialysis	No	graft, endarterectomy, aneury stent insertion		11251
Lower limb arterial revascularisation (i.e. stent or bypass procedure)	. angioplasty or	No	Has severe respiratory dis	sase	No	Non-traumatic amputation		No
		Nee		d or spread within approximately non-melanoma skin cancer)	No	New diagnosis of diabetes me	litus	No.
Aortic aneurysm repair (surgery or stent Has the participant been diagnosed with		Yes	Has a history of any other	medical condition that might al treatments for the duration of	No	Diagnosis of, or treatment for, melanoma skin cancer)	cancer (except non-	No
	1,510,53,53,53	63 Tr.	the study			Has the participant had any ot since their last visit?	her SERIOUS adverse events	No







Participar	nt ID		60001451		NHS (or CHI	number in Scotland	i)		Participant ID 40	50001451	
National	Identifier				Participant I	nitials	AB		Date of birth 01	1-Jan-1950	
Participar	nt Name	1	Anna Bulliva	int	Date of Birth	1	01-jan-1950		Sex Fe	emale	
Sex		3	female								
LCC		1	Vew site DE	MO UK (41598)					Race M	lixed	
	Laborator	/ Results Tab	le								nization visit rse Events
lyocardial	Date	Source	Kit ID	ALT (ULN)	AST (ULN)	Bilirubin (ULN)	Alkaline phosphatase (ULN)	Creatinine	eGFR		No No No
oronary a oronary a	13-Sep- 2019	Local Laboratory	,	100.00 (50.00) IU/L	60.00 (50.00) IU/L	20.0 (22.0) µmol/L	300 (150) IU/L	120.00 µmol/L	39.69 mL/min/1.73m2	as invalid	No s No
	is procedure)	naanan (ne. ar	Probinant .	-		Has severe respirator	y disease mosed or spread within approximately	Na No	Non-traumatic amputation		No
ortic aneurys	sm repair (surg	ery or stent)		Yes			r than non-melanoma skin cancer)	NO	New diagnosis of diabetes mellitus		No
101014000000000000	ipant been dia	CO 10/02/00/00 PDM	abetes?	No		limit their ability to ta	ther medical condition that might ke trial treatments for the duration of	No	Diagnosis of, or treatment for, cance melanoma skin cancer)	er (except non-	No
		Terrel Content of Clifford				the study			Has the participant had any other SE since their last visit?	RIQUS adverse events	s No








Participa	ntID	460001451	NHS (or CHI number in Scotl	and)	Participant ID 460001451	
National	Identifier		Participant Initials	AB	Date of birth 01-Jan-1950	
Participa	nt Name	Anna Bullivant	Date of Birth	01-jan-1950	Sex Female	
Sex		Female			Proc. Mixed	
LCC		New site DEMO UK (415)	8)		Race Mixed	
	Labora	tory Results Table				vization visit: rse Events
	600010	cory cousting round				No
Myocardia	Dat			nization visit: dy medication		No
Coronary a	13-9			,		No
Coronary a	201					No
Stroke	22220	Medication			Statin dosage (mg)	s No
Lower limb	certai rea	aspirin				
stent or bypas	ss proced	atorvastatin			20	No
Aortic aneurys	sm repai					No.
Has the partic	ipant be					No
					e since their last visit?	events No





ORION-4 study, simulated patient and data – reproduced with permission





#### **SOURCES** OF ROUTINELY-COLLECTED DATA IN CLINICAL RESEARCH

- Hospital Episode Statistics (HES) Admitted Patient Care
- Other HES data sets (Accident and Emergency)
- Death certifications (Office for National Statistics)
- Disease specific registries (Cancer, UK Renal Registry)
- National Audit Programmes (Diabetes)
- Other (General Practice data, Prescribing data)







#### **CHALLENGES** OF ROUTINELY-COLLECTED DATA IN CLINICAL RESEARCH


- Completeness of linkage
- Data format issues
  - Multiple sources and formats
- Coding practice and data quality
- Timeliness of receiving data
  - may clash with regulatory requirements







### **IMPORTING** ROUTINELY-COLLECTED DATA IN CLINICAL RESEARCH



UNIVERSITY OF

Research Uni

- Check completeness of linkage
- Create a dataset-specific mask
  - Defines the data format and potential checks
- Review, clean and homogenise data
  - "Sanity checks" include the correct number of columns and whether the participant ID returned "belongs" to that registry
  - Some checks are automatic (if a column is marked as "date", ICD10, OPCS or similar)
  - Other checks and lists can be specified (using regular expressions)



### USING ROUTINELY-COLLECTED DATA IN CLINICAL RESEARCH

- Transform and import data automatically
- Use a bespoke data viewer:







# **A TALE OF THREE TRIALS**



Active Monitoring for AtriaL Fibrillation













Active Monitoring for AtriaL Fibrillation












# (Active Monitoring for AtriaL FIbrillation)



# AMALFI






http://www.isrctn.com/ISRCTN15544176





### USING PRIMARY CARE DATA FOR TRIALS




NHR National Institute for Health Research













AMALA





High risk population, identified from primary care electronic records: aged ≥65; CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥ 3 (men), ≥ 4 (women)

AGE (>64/>74) GENDER **HEART FAILURE HYPERTENSION** DIABETES STROKE/TIA/THROMBOEMBOLISM **VASCULAR DISEASE (HEART ATTACK, PAD)** 

Risk factor	Score
Congestive heart failure/LV dysfunction	1
Hypertension	Ť
Age > 75	2
Diabetes mellitus	1
Stroke/TIA/thromboembolism	2
Vascular disease*	1
Age 65-74	1
Sex category (ie, female sex)	1
Maximum score	9

Note: \*Prior myocardial infarction; peripheral artery disease; aortic plaque. Abbreviations: LV, left ventricular; TIA, transient ischemic attack.

#### CHA<sub>2</sub>DS<sub>2</sub>VASC SCORE






MALE

Active Monitoring for Atrial, Fibrillation












emis

#### (or other systems)

🦳 🖸 🏠 💋 😂 🖻 🕫 💐 🔍 🖌 E	EMIS Web Health Care System - BROADSHIRES HEALTH CENTRE - 467 - 🗖	×
Population Reporting Enquiry Manager FF	D Reports MIQUEST Batch Data Manager	
Add Properties X Cut Copy Add Properties Paste Export Add / Edit SCR - 19 Test Requests - 2284 GP2GP - 6		
New priority Workflow Items received - Media		×
BROADSHIRES HEALTH CENTRE Name	Population Count % Last Run Search Type Scheduled	_
🔺 🟯 BROADSHIRES HEALTH CENTI 🔺 🖉 Fen	es >64 yrs for Chads Vasc 4 or more 627 6% 14-May-2019 Patient	
🕨 🛅 AAA Pt Safety Folder 🛛 📃 🔎	ad Vasc 3 or more 202 32% 14-May-2019 Patient	
Alison's Searches	Patient List + Address Patient	
🖻 🦾 Anna's Searches 🖉 🖉 Mak	>64 yrs for CHads Vasc 3 or more 560 5% 14-May-2019 Patient	
Casey's Searches	ad Vasc 3 or more 199 36% 14-Mav-2019 Patient	
Christine s Searches	Patient List + Address Patient	
A Cavity Homeoning in		
AF-GEN		
C AMALFI		
🛅 AMICA - Aortic Steno:		
ARCHIE		
DUDITS for Appraisal		
BARACK revised BARCODE 1		
BEST3		
▷ C BEST3 (2)		
BOLD		
E BPD Chad V	sc 3 or more	
CCP Details	finition Age / Sex Trend Population Included Population Excluded	
CHESS Parent P	ulation Males >64 yrs for CHads Vasc 3 or more	
Code Sy	m Read v2 🕦	
COMET CODE Sy	A'COURT, Christine (Dr) Date Modified 14-May-2019	
BROADSHIRES HEALTH CENTRE	14-May-2019 17:40 Relative Date 14-May-2019 17:39	
GP Contract - QOF Popula	n Parent % Excluded	
EMIS Library	560         36%         361	
Oxfordshire (SCWCSU/OCCG)		
»		
Clinical Practitioner   A'COURT, Christ	(Dr)   Location: BROADSHIRES HEALTH CENTRE   🖌 🖌 Available	? Ale
	🔿 🤌 A COURT, Christi 📀 Informatica 🛛 💽 EMIS Configurati 🔐 EMIS Web Health 🗰 Females EMIS Sea 🗰 Males EMIS Searc 🔺 🔛 🌒	28













Or



the Clinical Code is [V]Pallative care






iule 2		If Rule Passed 1 Include in fir	sal result	If Rule Failed	r Goto Next Rule
Must have And	Include Patients with Clinical Codes where: the Clinical Code is Heart failure. Left ventricular systolic dysfunction, Echocardiogram shows left ventricular systolic dysfunction Include Patients with Clinical Codes where: the Clinical Code is Hypertensive disease	HF + HTN			
ule 3		If Rule Passed : Include in final	I result	If Rule Fuiled :	Goto Next Rule
Must have And	Include Patients with Clinical Codes where: the Clinical Code is Heart failure, Left ventricular systolic dysfunction, Echocardiogram shows left ventricular systolic dysfunction Enclude Patients with Clinical Codes where: the Clinical Code is Diabetes mellitus	Н	F + D	Μ	
de 4		If Rule Passed : Include in final	result -	If Rule Failed :	Goto Next Rule
ust have	Include Patients with Clinical Codes where: the Clinical Code is Heart failure. Left ventricular systolic dysfunction. Echocardiogram shows left ventricular systolic dysfunction.				
nd	Include Patients with Clinical Codes where: the Clinical Code is Other peripheral vascular disease (excluding Upper limb is chaemia, Raynaud's syndrome, Thromboangitis obliteral	ns and HAVS - Hand-arm vibration syndrom	e), Peripheralv	rascular disease NOS, (	tc
		н	F + P/	AD	













doitsplayHams)Climical Codet/displayHamp>







## **FEASIBILITY & PLANNING**













## **FEASIBILITY & PLANNING**






















AMALE,
















## **TRIAL DESIGN**






UNIVERSITY OF OXFORD

https://clinicaltrials.gov/ct2/show/NCT03705234 Image source: www.timi.org



## **USING SECONDARY CARE DATA FOR TRIALS**

HPS-4





## **PROTOCOL DESIGN**

VS


#### Simple inclusion criteria:

Age  $\geq$ **55y** and:

- 1- Prior myocardial infarction; or
- 2- Prior ischaemic stroke; or
- 3- Peripheral vascular disease

(prior lower extremity artery revascularization or aortic aneurism repair)

#### "Standard" inclusion criteria:











# **PROTOCOL DESIGN**

#### Simple inclusion criteria:

Age  $\geq$ **55y** and:

- 1- Prior myocardial infarction; or
- 2- Prior ischaemic stroke; or
- 3- Peripheral vascular disease

(prior lower extremity artery revascularization or aortic aneurism repair) Simple **electronic search** criteria:

1- Diagnosis of **MYOCARDIAL INFARCTION**: ICD9 codes: 410\*, 412\* and/or ICD10 codes: I21\*, I22\*, I23\*, I252 and/or READ codes: G30\*

2- Diagnosis of STROKE:
ICD9 codes: 433\*, 434\* and/or
ICD10 codes: I63\*, I64\* and/or
READ codes: G63\*, G64\*, G66 and/or

3- Surgery/procedure for **PERIPHERAL VASCULAR DISEASE**: OPCS-4 procedure codes: L16\*-L28\* inclusive,

L48\*-65\* inclusive, L71\*











## **FEASIBILITY & PLANNING**


















# **IDENTIFICATION & INVITATION**













# **IDENTIFICATION & INVITATION**















SEARCH THRIVE REVEAL

Late 2000s

Early 2000s

Early 2010s

Invite

Screen

Run-in


Randomise

#### Conversion









NHR National Institute for Health Research
















## **ASCEND**

Phase 4, double-blind, randomized, 2 × 2 factorial primary prevention study in patients with diabetes but no overt CVD



- Primary efficacy outcome: first serious vascular event (MI, stroke, TIA) or death from any vascular cause (excluding ICH)
- Primary safety outcome: first major bleeding event (ie, ICH, sight-threatening bleeding, GI bleeding, or other serious bleeding)
- Secondary outcomes: included GI tract cancer .




Research Unit

ASCEND study collaborative group. NEJM 2018;379:1529-1539 ClinicalTrials.gov: NCT00135226 Figure source: www.medscape.com





## **USING <u>ROUTINE DATA</u> DATA FOR TRIALS**



Research Un





## INVITATION

#### Recruitment and follow-up entirely by mail (no sites)

	Diabetes registries	General practices	Traditional sources	Overall
Invited	300,000	120,000	2,300	422,300
Responded	100,000	20,000	1,200	121,200
	(33%)	(17%)	(~50%)	(~29%)
Randomized	9,000	6,000	400	15,400
	(3%)	(5%)	(17%)	(~3.6%)





detion Healt



# **OUTCOME COLLECTION**

- Postal questionnaires/GP review
- Targeted **HES search** and clinician review if lost to FU
  - Enabled **99% completeness of follow-up** (vs ~94% without HES)
- Automated 'event' creation (e.g. death notification)
  - Usually followed by manual review by trial clinician







## **OUTCOME COLLECTION**

(bespoke HES data viewer)









# **OUTCOME COLLECTION**

How does routinely-collected data compare against clinician adjudication?

#### Hospital Episode Statistics (England and Wales)



# **Clinician adjudication** "Gold Standard"









## **OUTCOME COLLECTION** (excluding Scotland)









## **OUTCOME COLLECTION** (excluding Scotland)









## **OUTCOME COLLECTION** (excluding Scotland)








## **OPPORTUNITIES: POST-TRIAL FOLLOW-UP (WOSCOPS study)**

Routinely-collected records in Scotland (Scottish Morbidity Record)











## **OPPORTUNITIES FOR ROUTINELY-COLLECTED DATA: INCLUSIVE TRIALS**



**Randomized patients (ASCEND)** 




NHS Trusts involved (ORION-4)








## **OPPORTUNITIES AND CHALLENGES FOR ROUTINELY-COLLECTED DATA: DATA-ENABLED CLINICAL TRIALS**











MRC


## Harnessing routinely-collected data for

## efficient and low-cost clinical trials

### **Guilherme Pessoa-Amorim**

NIHR Clinical Research Fellow

Clinical Trial Service Unit & Cardiovascular Medicine Division, University of Oxford





iffield Department of OPULATION HEALTH edical Sciences Division



